ISRCTN47862456 https://doi.org/10.1186/ISRCTN47862456

Randomised trial of ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE) versus standard practice chemotherapy in patients with limited small cell lung cancer (SCLC) and good performance status

Submission date 06/04/2000	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol
Registration date 06/04/2000	**Overall study status** Completed	[_] Statistical analysis plan [X] Results
Last Edited 02/09/2022	**Condition category** Cancer	[_] Individual participant data

Plain English summary of protocol
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/lu21-chemotherapy-for-small-cell-lung-cancer

Contact information

Type(s)
Scientific

Contact name
Dr Danielle Andrews

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00002822

Protocol serial number
LU21

Study information

Scientific Title
Randomised trial of ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE) versus standard practice chemotherapy in patients with limited small cell lung cancer (SCLC) and good performance status

Study objectives
To compare an intensive regimen of VICE without dose reduction but with dose delay permitted versus standard practice chemotherapy in patients with limited stage SCLC and good performance status

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Cancer

Interventions
1. One group receives intensive regimen of VICE without dose reduction but with dose delay permitted
2. The other group receives standard practice chemotherapy

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
ifosfamide, carboplatin and etoposide with mid-cycle vincristine (VICE)

Primary outcome(s)
Survival time, quality of life

Key secondary outcome(s)
Not provided at time of registration

Completion date
01/12/2001

Eligibility

Key inclusion criteria
1. Previously untreated SCLC
2. Limited disease
3. WHO 0-2
4. Normal blood count
5. Glomerular Filtration Rate (GFR) greater than 65 ml/min

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Total final enrolment
402

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/12/1995

Date of final enrolment
01/12/2001

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	20/11/2005		Yes	No
Plain English results			02/09/2022	No	Yes